Notable Wednesday Option Activity: MCK, RKLB, BMY

Rocket Lab (RKLB) saw 119,845 options contracts trade (≈12.0M underlying shares), about 47.5% of its one-month average daily volume (25.2M), with elevated activity in the $70 put expiring Feb 6, 2026 (3,659 contracts ≈365,900 shares). Bristol Myers Squibb (BMY) recorded 59,498 contracts (≈5.9M shares), about 46.9% of its one-month ADTV (12.7M), led by the $55 put expiring Feb 13, 2026 (7,697 contracts ≈769,700 shares). The prints indicate significant put interest and heavy options flow in both names that could amplify intraday price moves.

Analysis

Market structure: The concentrated put flow in RKLB (119,845 contracts ≈12.0M shares, ~47.5% of ADV) and BMY (59,498 contracts ≈5.9M shares, ~46.9% of ADV) signals large institutional directional or hedging activity rather than retail noise. That order flow will push up implied volatility (IV) and skew, force dealer delta-hedging (likely selling stock into weakness) and create short-term liquidity demand in the underlying over the next 3–10 trading days. Expect increased bid/ask friction and wider spreads for RKLB (small-cap, higher gamma) versus BMY (large-cap, lower gamma) with potential short-term negative price pressure concentrated near the concentrated strikes ($70 RKLB, $55 BMY).

Risk assessment: Tail risks differ by name — RKLB is exposed to operational/financing tail risk (launch failure, equity raise) that could cascade into accelerated dilution within 3–6 months; BMY faces regulatory or trial headlines with event risk over 1–12 months. Hidden dependency: large long-dated put buys (Feb 2026) suggest either long-term hedges or block trades tied to other OTC or structured notes; unwind could be abrupt if buyers are hedgers. Catalysts to watch in the next 30–90 days: 13F/13D/8-K filings, scheduled trials/earnings, and any announced equity offerings.

Trade implications: Short-term (days–weeks) trade the volatility dislocation: for RKLB, prefer buying a defined-risk put spread (buy Feb-2026 $70/$50) sized 0.5–1.5% notional if price breaches $70; avoid outright long puts if IV > historical 90th percentile. For BMY, consider selling a 60–90 day put spread (sell $55 / buy $50) for credit if IV stays elevated and fundamentals intact, or buy cheap downside protection only if downside risk >5–8% vs current levels. Pair trade: long BMY vs short a mid-cap biotech (e.g., size 1:1) to capture defensive rotation; cap individual trades to 1–2% NAV.

Contrarian angles: Consensus treats heavy put flow as pure bearish conviction, but much could be portfolio protection — if these are hedges, dealer hedging can create transient downward momentum that reverses on option expiry or hedger unwind. Reaction may be overdone in RKLB where large puts can exacerbate illiquidity and create short-term squeezes if fundamentals hold; conversely, BMY’s large-cap liquidity reduces structural downside, making income-selling strategies attractive. Historical parallels: large put blocks preceding secondary offerings (weeks–months lead); monitor for issuance signals to avoid being long into dilution.

Key Decisions for Investors

• RKLB: If RKLB trades at or below the $70 strike within 10 trading days, establish a defined-risk bearish position sized to 0.5–1.5% of NAV by buying the Feb 2026 $70/$50 put spread (limit max loss to premium paid); this captures downside while capping cost in elevated IV.
• BMY: Sell a 60–90 day put spread (sell Feb/Mar 2026 $55 / buy $50) for a net credit sized to 1% NAV if BMY remains above $58 and IV stays >30th percentile — target yield >4% annualized on notional, stop-loss if underlying falls >6% intraday.
• Volatility arbitrage: Enter a calendar skew trade when short-term IV > long-term IV by selling 30–45 day calls or strangles on RKLB/BMY and buying the Feb-2026 wings to convert into a calendar/diagonal, size overall vega exposure to <1% NAV and reassess weekly.
• Information triggers to act on (monitor next 30–90 days): take profits or unwind directional positions on filings (13D/8-K), announced equity offerings, or large insider/10b5-1 activity; if a 13F/13D or shelf appears for RKLB, trim long-risk immediately and size shorts up to 1–2% NAV.